Benzinga | Nov 30, 2021 04:43PM EST

Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer

* Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals

* Robust anti-tumor activity, including three partial responses (two confirmed and one unconfirmed) and up to 100% target lesion reduction, observed in a heavily pretreated patient population

* Overall Response Rate of 17% and Clinical Benefit Rate of 46% in recommended Phase 2 dose range; Efficacy data continues to mature with 32% of patients still on study

* Rapidly advancing clinical development program with dose expansion ongoing; Phase 2 monotherapy and first CDK4/6 inhibitor combination studies to initiate in Q1 2022

* Company to host investor conference call today at 8:30 a.m. ET